Elias Lagonik

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Gene Expression

Tyrosine Kinase

Chronic Myeloid Leukemia

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Laura N Eadie, Elias Lagonik, Elyse C Page, Caitlin E Schutz, Susan L Heatley, Barbara J McClure, Michelle O Forgione, David T O Yeung, Timothy P Hughes, Deborah L White
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood 144 (9) (2024)
Laura N Eadie, Elias Lagonik, Elyse C Page, Caitlin E Schutz, Susan L Heatley, Barbara J McClure, Michelle O Forgione, David T O Yeung, Timothy P Hughes, Deborah L White
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood 144 (9) (2024)
Laura N Eadie, Elias Lagonik, Elyse C Page, Caitlin E Schutz, Susan L Heatley, Barbara J McClure, Michelle Olivia Forgione, David T O Yeung, Timothy P Hughes, Deborah L White
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood (2024)